Efficacy, Safety, and Drug–Drug Interactions for Insomnia Therapy in COVID-19 Patients
Billy Dwi Saputra,Jutti Levita,Resmi Mustarichie
DOI: https://doi.org/10.2147/JMDH.S337053
2022-01-21
Journal of Multidisciplinary Healthcare
Abstract:Billy Dwi Saputra, 1 Jutti Levita, 2 Resmi Mustarichie 3 1 Undergraduate Program of Pharmacy, Faculty of Pharmacy, Universitas Padjadjaran, Sumedang, 45363, Indonesia; 2 Department of Pharmacology and Clinical Pharmacy, Faculty of Pharmacy, Universitas Padjadjaran, Sumedang, 45363, Indonesia; 3 Department of Pharmaceutical Analysis and Medicinal Chemistry, Faculty of Pharmacy, Universitas Padjadjaran, Sumedang, 45363, Indonesia Correspondence: Resmi Mustarichie Department of Pharmaceutical Analysis and Medicinal Chemistry, Faculty of Pharmacy, Universitas Padjadjaran, Sumedang, 45363, Indonesia Tel +6222-84288888 Ext 3510 Email Coronavirus disease-19 (COVID-19) is a systemic viral infection. COVID-19 patients show diverse clinical presentations ranging from asymptomatic, mild symptoms to severe symptoms characterized by severe respiratory distress. Sleep disorders or insomnia is one of the psychiatric problems that arise during the COVID-19 pandemic. The term used to define this particular insomnia is coronasomnia or COVID-19 insomnia. Data show that the prevalence of this problem is increasing, especially in the confirmed COVID-19 patient group. Anti-insomnia drugs such as hypnotics, sedatives, and anxiolytics are the easiest option. As with drugs generally, anti-insomnia drugs are associated with various safety issues, especially in people with COVID-19. Therefore, their use may be hazardous. The literature review aims to make health practitioners aware of the anti-insomnia drugs that have the best efficacy and safety issues that are clinically relevant from the use of anti-insomnia drugs and the interactions of anti-insomnia drugs with various drugs used in the treatment of COVID-19. The articles were explored on PubMed and Cochrane Library, whereas the drug–drug interactions between the anti-insomnia and COVID-19 drugs were searched on Drugs.com Interaction Checker and Lexiomp-interact. Overall anti-insomnia drugs have efficacy in improving sleep parameters. Orexin receptor antagonist drugs have good efficacy in increasing WASO, LPS, and SE with an acceptable safety profile. Meanwhile, the combination of zolpidem, lorazepam, and diphenhydramine improved TST parameters better than other drugs. Side effects such as drowsiness and dizziness were among the most commonly reported effects. Therefore, attention and monitoring of the use of anti-insomnia drugs in COVID-19 patients need to be carried out by considering the side effects and interactions that are very risky. Keywords: insomnia, COVID-19, polysomnography, efficacy, safety, interaction The Coronavirus Disease (COVID-19) pandemic is a condition that requires rapid handling and adjustment, especially in the health sector. Among various health fields, psychiatry is a medical field that is also affected by this pandemic. COVID-19 is a systemic viral infection that attacks many organs and work processes of the body. The respiratory tract is the main organ that is affected and disturbed. COVID-19 patients show diverse clinical presentations ranging from asymptomatic, mild symptoms to severe symptoms characterized by severe respiratory distress. COVID-19 is associated with hypoxic respiratory distress and can rapidly progress to acute respiratory distress syndrome (ARDS). 1 The risk of severity and death from this disease increases in people with old age and comorbidities. 2 COVID-19 patients have the possibility of experiencing psychiatric symptoms or problems due to the impact of diagnosis communication, forced isolation, the medical symptoms caused, and the risk of death. In addition, medical care and medication also trigger psychiatric problems. Sleep disorders or insomnia is one of the psychiatric problems that arise during COVID-19 pandemic. The term used to define this particular insomnia is Coronasomnia or COVID-19 insomnia. 3 COVID-19 insomnia is manifested by lack of sleep at night, sleepiness during the day, and an increased need for naps, which are associated with physical and psychological problems that occur during COVID-19 infection. This sleep disorder occurs due to disrupted circadian rhythm during isolation and increased cytokines due to infection that interferes with both non-REM and REM sleep sleep. 4,5 Data shows that the prevalence of sleep problems during the COVID-19 pandemic is increasing and affecting society globally, especially in the confirmed COVID-19 patient group, which is 74.8%, followed by an increase in the use of sleeping pills. 6,7 Anti-insomnia drugs such as hypnotics, sedatives, and anxiolytics are the easiest option to treat insomnia. However, as with drugs generally, anti-insomnia drugs are associated with various safety issues, especially in people with COVID-19. Therefore, their use ma -Abstract Truncated-
health care sciences & services